keyword
https://read.qxmd.com/read/38752169/childhood-intestinal-parasitic-reinfection-sanitation-and-hygiene-practice-in-eastern-ethiopia-case-control-study
#1
JOURNAL ARTICLE
Heroda Gebru, Negussie Deyessa, Girmay Medhin, Helmut Kloos
BACKGROUND: The recurrence of intestinal parasitic infections (IPIs) can lead to different problems that can be transferred from generation to generation. Sanitation and hygienic practices have vital role in the parasitic reinfection. In poor hygienic and sanitation condition children may live in a continuous cycle of infection and reinfection. OBJECTIVE: To assess childhood IP reinfection and its association with sanitation and hygienic practice in eastern Ethiopia...
2024: Infection and Drug Resistance
https://read.qxmd.com/read/38749440/-malignant-lymphomas-quo-vadis-what-developments-await-us-in-diagnostics-and-therapy
#2
JOURNAL ARTICLE
Stefan Alig, Christiane Pott, Björn Chapuy
The diagnosis and treatment of malignant lymphoma is rapidly advancing, offering hope but also highlighting inherent limitations. Technological breakthroughs in sequencing technologies enable more precise subtyping and risk stratification. For example, in diffuse large B-cell lymphoma (DLBCL), exome sequencing revealed molecular subtypes. Understanding these subtypes sheds light on lymphomagenesis and prognosis, and may provide targets for tailored therapies. Additionally, tumor-derived cell-free DNA (ctDNA) detected in blood plasma allows for genotyping, risk stratification, and measurement of minimal residual disease (MRD)...
May 2024: Deutsche Medizinische Wochenschrift
https://read.qxmd.com/read/38743005/prognostic-significance-of-myeloid-derived-suppressor-cells-and-systemic-inflammation-in-newly-diagnosed-diffuse-large-b-cell-lymphoma-treated-with-chemoimmunotherapy
#3
JOURNAL ARTICLE
David M Foureau, Fei Guo, Nury M Steuerwald, Lawrence J Druhan, Belinda R Avalos, Edward Copelan, Danyu Sun, Bei Hu, Tamara Moyo, Ryan Jacobs, Steven Park, Nilanjan Ghosh
The revised International Prognostic Index (R-IPI) is an important prognostic tool in diffuse large B cell lymphoma (DLBCL); however, outcomes can vary markedly within R-IPI groups, and additional prognostic markers are needed. We conducted a prospective observational study to evaluate the circulating immature myeloid (IM) cell subsets and cytokine profiles of 31 patients with newly diagnosed DLBCL before and after chemoimmunotherapy. Among circulating IM cells, myeloid-derived suppressor cells (MDSCs) were the predominant cell type (73...
January 2024: Experimental Hematology
https://read.qxmd.com/read/38742655/soluble-mic-a-ipi-and-response-to-treatment-strongly-predict-survival-in-patients-with-germinal-center-diffuse-large-b-cell-lymphoma
#4
JOURNAL ARTICLE
Jorge Vela-Ojeda, Ana Cristina Olivas-Bejarano, Laura Arcelia Montiel-Cervantes, Erika Rosales-Cruz, Socrates Garcia-Gutierrez, Ruth Angelica Lezama-Palacios, Elba Reyes-Maldonado
UNLABELLED: Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoma. MIC-A and MIC-B are the natural ligands for NKG2D, a receptor expressed in NK cells. MIC-A soluble isoforms (sMICA) have been described in different malignancies. OBJECTIVES: To analyze lymphocyte subsets and sMIC-A in germinal center DLBCL. MATERIALS AND METHODS: sMICA, sMICB, and peripheral blood lymphocyte subsets (CD4+, CD8+, NK, NKT, γδ T cells, and dendritic cells) were analyzed in 59 patients and 60 healthy donors...
May 14, 2024: European Journal of Haematology
https://read.qxmd.com/read/38734435/the-association-of-the-hepatitis-b-virus-infection-and-diffuse-large-b-cell-lymphoma
#5
JOURNAL ARTICLE
Guodong Yu, Jijing Han, Jianmei Xu
OBJECTIVES: To investigate the basic characteristics of patients with diffuse large B-cell lymphoma (DLBCL) and whether hepatitis B surface antigen positive (HBsAg [+]) affects the survival of patients with DLBCL. METHODS: The study was carried out at Affiliated Hospital of Hebei University, Baoding, China, including 602 DLBCL cases from January 2011 to December 2021. We analyzed patients' general clinical data and applied multivariate and univariate Cox analyses to assess the factors influencing their survival times...
May 2024: Saudi Medical Journal
https://read.qxmd.com/read/38721589/intestinal-parasitic-infections-and-predisposing-factors-among-prison-inmates-in-southern-ghana-a-cross-sectional-study
#6
JOURNAL ARTICLE
Albert Abaka-Yawson, Daniel S Squire, Benedict Osei Tawiah, John Arko-Mensah
BACKGROUND AND AIMS: The environment within prisons, such as overcrowding, lack of access to portable water, poor sanitation, and hygiene predisposes inmates to infections, including intestinal parasitic infections (IPIs). This study therefore determined the prevalence and associated factors of IPIs among prison inmates in Southern Ghana. METHODS: A cross-sectional study using the stratified sampling technique was employed. The study recruited 461 prison inmates across three notable prisons, with 50 inmates from Ho Central, 357 inmates from Nsawam Medium Security, and 54 inmates from Sekondi Central Prisons all in Southern Ghana...
May 2024: Health Science Reports
https://read.qxmd.com/read/38705953/evaluating-the-efficacy-and-safety-of-nivolumab-and-ipilimumab-combination-therapy-compared-to-nivolumab-monotherapy-in-advanced-cancers-excluding-melanoma-a-systemic-review-and-meta-analysis
#7
COMPARATIVE STUDY
Hussain Sohail Rangwala, Hareer Fatima, Mirha Ali, Sailesh Sunder, Sonia Devi, Burhanuddin Sohail Rangwala, Syed Raza Abbas
BACKGROUND: Nivolumab (Nivo) and ipilimumab (Ipi) have revolutionized cancer treatment by targeting different pathways. Their combination shows promising results in various cancers, including melanoma, but not all studies have demonstrated significant benefits. A meta-analysis was performed to assess the effectiveness and safety of Nivo-Ipi compared to Nivo alone in advanced cancer types (excluding melanoma). METHODS: Following PRISMA guidelines, we conducted a meta-analysis up to September 30, 2023, searching databases for randomized controlled trials (RCTs)...
May 6, 2024: Journal of the Egyptian National Cancer Institute
https://read.qxmd.com/read/38695475/the-predictive-value-of-the-inflammatory-prognostic-index-for-detecting-no-reflow-in-st-elevation-myocardial-infarction-patients
#8
JOURNAL ARTICLE
Faysal Şaylık, Tufan Çınar, İbrahim Halil Tanboğa
BACKGROUND: No-reflow (NR) is characterized by an acute reduction in coronary flow that is not accompanied by coronary spasm, thrombosis, or dissection. Inflammatory prognostic index (IPI) is a novel marker that was reported to have a prognostic role in cancer patients and is calculated by neutrophil/lymphocyte ratio (NLR) multiplied by C-reactive protein/albumin ratio. OBJECTIVE: We aimed to investigate the relationship between IPI and NR in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (pPCI)...
2024: Arquivos Brasileiros de Cardiologia
https://read.qxmd.com/read/38694041/development-of-sustainable-dual-core-spun-yarns-using-several-filaments-and-recycled-cotton-sourced-from-pre-consumer-fabric-waste
#9
JOURNAL ARTICLE
Ahsan Habib, Md Abdullah Al Mamun, Osman Babaarslan
Textile industries are now focusing on sustainable issues in manufacturing operations to save the environment. The study focuses on the use of cotton fibers (recycled) sourced from fabric (knitted) waste (pre-consumer) to manufacture elastic yarn (dual-core) for denim fabric. The study involves the production of yarns (dual-core) using a redesigned ring spinning method with different elastomeric components, including T400® (Polyethylene terephthalate)/Polytrimethylene terephthalate), Polybutylene terephthalate (PBT), Polyester (PES), Lycra® (elastane), virgin cotton and cotton (recycled) fiber...
May 15, 2024: Heliyon
https://read.qxmd.com/read/38692937/turning-the-tide-in-aggressive-lymphoma-liquid-biopsy-for-risk-adapted-treatment-strategies
#10
REVIEW
Steven Wang, Florent Mouliere, D Michiel Pegtel, Martine E D Chamuleau
Diffuse large B cell lymphoma (DLBCL) exhibits significant biological and clinical heterogeneity that presents challenges for risk stratification and disease surveillance. Existing tools for risk stratification, including the international prognostic index (IPI), tissue molecular analyses, and imaging, have limited accuracy in predicting outcomes. The therapeutic landscape for aggressive lymphoma is rapidly evolving, and there is a pressing need to identify patients at risk of refractory or relapsed (R/R) disease in the context of personalized therapy...
May 1, 2024: Trends in Molecular Medicine
https://read.qxmd.com/read/38691750/dynamically-manipulating-long-wave-infrared-polarized-thermal-radiation-by-a-vanadium-dioxide-metasurface
#11
JOURNAL ARTICLE
Qianlong Kang, Kai Guo, Xizheng Zhang, Wei Wang, Zhongyi Guo
Dynamically manipulating the spectra and polarization properties of thermal radiation is the key to counter an infrared polarization imaging system (IPIS) under the different background environments. In this Letter, we propose a phase-change metasurface thermal emitter (PCMTE) composed of vanadium dioxide (VO2 ) dipole antenna arrays to dynamically manipulate polarized radiation spectra in the long-wave infrared (LWIR) region of 8-14 µm. During the thermally induced and reversible insulator-to-metal transition (IMT) in VO2 , by simulating the LWIR images at different polarization angles for the PCMTE and background plates, the PCMTE can realize dynamically tunable LWIR camouflage; then, their degree of linear polarization (DoLP) can be calculated, which can demonstrate that the PCMTE can also achieve dynamically tunable LWIR polarization camouflage at the specific radiation angles and backgrounds...
May 1, 2024: Optics Letters
https://read.qxmd.com/read/38672547/development-and-validation-of-an-inflammatory-prognostic-index-to-predict-outcomes-in-advanced-metastatic-urothelial-cancer-patients-receiving-immune-checkpoint-inhibitors
#12
JOURNAL ARTICLE
Sara Mokbel, Giuilia Baciarello, Pernelle Lavaud, Aurelius Omlin, Fabio Calabrò, Richard Cathomas, Stefanie Aeppli, Pauline Parent, Patrizia Giannatempo, Kira-Lee Koster, Naara Appel, Philippe Gonnet, Gesuino Angius, Petros Tsantoulis, Hendrick-Tobias Arkenau, Carlo Cattrini, Carlo Messina, Jean Zeghondy, Cristina Morelli, Yohann Loriot, Vincenzo Formica, Anna Patrikidou
BACKGROUND: Immune checkpoint inhibitors (ICIs) improve overall survival (OS) in advanced/metastatic urothelial cancer (a/mUC) patients. Preliminary evidence suggests a prognostic role of inflammatory biomarkers in this setting. We aimed to develop a disease-specific prognostic inflammatory index for a/mUC patients on ICIs. METHODS: Fifteen variables were retrospectively correlated with OS and progression-free survival (PFS) in a development (D, n = 264) and a validation (V, n = 132) cohort of platinum-pretreated a/mUC pts receiving ICIs at L2 or further line...
April 11, 2024: Cancers
https://read.qxmd.com/read/38672542/predictors-of-survival-treatment-modalities-and-clinical-outcomes-of-diffuse-large-b-cell-lymphoma-in-patients-older-than-70-years-still-an-unmet-medical-need-in-2024-based-on-real-world-evidence
#13
JOURNAL ARTICLE
Luís Alberto de Pádua Covas Lage, Rita Novello De Vita, Lucas Bassolli de Oliveira Alves, Mayara D'Auria Jacomassi, Hebert Fabrício Culler, Cadiele Oliana Reichert, Fábio Alessandro de Freitas, Vanderson Rocha, Sheila Aparecida Coelho Siqueira, Renata de Oliveira Costa, Juliana Pereira
BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) especially affects the older population. Old (≥60 years) and very old age (≥80 years) DLBCL patients often present high-risk molecular alterations, lower tolerability to conventional immunochemotherapy, and poor clinical outcomes. In this scenario, attenuated therapeutic strategies, such as the R-MiniCHOP and R-MiniCHOP of the elderly regimens, have emerged for this particularly fragile population. However, the responses, clinical outcomes, and toxicities of these regimens currently remain poorly understood, mainly because these individuals are not usually included in controlled clinical trials...
April 11, 2024: Cancers
https://read.qxmd.com/read/38660852/-correlation-analysis-of-peripheral-blood-b-cell-count-with-clinical-features-and-prognosis-in-patients-newly-diagnosed-with-diffuse-large-b-cell-lymphoma
#14
JOURNAL ARTICLE
Tian Lu, Hao Mi, Dan-Dan Zhao, Shui-Ge Yang, Yun-Wen Bu, Fang Zhang, Wen-Ming Chen, Dao-Ping Sun
OBJECTIVE: To explore the correlation between peripheral blood B cell count and clinical features and prognosis of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). METHODS: The relationship of peripheral blood B cell count with clinical features, laboratory indexes and prognosis in 67 patients with newly diagnosed DLBCL was retrospectively analyzed. RESULTS: Patients were divided into low B-cell count group (B cell<0...
April 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://read.qxmd.com/read/38660851/-expression-of-cd30-in-patients-with-diffuse-large-b-cell-lymphoma-and-clinical-significance
#15
JOURNAL ARTICLE
Yang Qu, Xu-Zhang Lu, Rong-Xuan Wang, Xiao-Fei Hei, Jin Li, Bi-Tao Xiao, Zhu-Xia Jia
OBJECTIVE: To investigate the expression and clinical significance of CD30 in patients with diffuse large B-cell lymphoma (DLBCL). METHODS: A retrospective analysis was conducted on 124 cases of primary DLBCL diagnosed at Changzhou Second People's Hospital Affiliated with Nanjing Medical University from January 2018 to July 2020. The expression of CD30 in patients with DLBCL was detected by immunohistochemical method, and the clinicopathological characteristics were analyzed and compared between CD30+ and CD30- groups...
April 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://read.qxmd.com/read/38660849/-the-value-of-baseline-pet-ct-imaging-of-bone-marrow-18-f-fdg-uptake-pattern-in-predicting-prognosis-of-dlbcl
#16
JOURNAL ARTICLE
Yuan Wang, Ming Zhao, Ling Yuan, Juan Li
OBJECTIVE: To investigate the prognostic value of bone marrow uptake pattern in 18 F-deoxyglucose (18 F-FDG) PET/CT imaging before diffuse large B-cell lymphoma (DLBCL) treatment. METHODS: The clinical data of 156 patients with DLBCL were retrospectively analyzed. All patients underwent bone marrow biopsy, bone marrow smear, flow cytometry and 18 F-FDG PET/CT scan before treatment. Taking normal liver 18 F-FDG uptake as the standard, the bone marrow uptake patterns of patients were divided into three types: focal increased bone marrow uptake (fPET+ ), diffusely increased bone marrow uptake (dPET+ ), and normal bone marrow uptake (nPET)...
April 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://read.qxmd.com/read/38660847/-a-real-world-single-center-study-of-adult-hodgkin-s-lymphoma
#17
JOURNAL ARTICLE
Ling-Li Wang, Lei Tian, Fei Dong, Ping Yang, Wei Wan, Qi-Hui Li, Lan Ma, Jin-Jie Gao, Ji-Jun Wang, Wei Zhao, Hong-Mei Jing
OBJECTIVE: To summarize the clinical characteristics, therapeutic effect and prognostic factors of patients with Hodgkin's lymphoma (HL). METHODS: A total of 129 patients with HL diagnosed in Peking University Third Hospital from January 2010 to March 2021 who were given at least one efficacy assessment after treatment were enrolled, and their clinical data, including sex, age, pathological type, Ann Arbor stage, ECOG score, blood test, β2 -microglobulin, lactate dehydrogenase level, albumin level were collected...
April 2024: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://read.qxmd.com/read/38633747/derangements-of-immunological-proteins-in-hiv-associated-diffuse-large-b-cell-lymphoma-the-frequency-and-prognostic-impact
#18
JOURNAL ARTICLE
Jenifer Vaughan, Moosa Patel, Melinda Suchard, Maemu Gededzha, Heena Ranchod, Wayne Howard, Tracy Snyman, Tracey Wiggill
INTRODUCTION: Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy of B-cells frequently encountered among people living with HIV. Immunological abnormalities are common in immunocompetent individuals with DLBCL, and are often associated with poorer outcomes. Currently, data on derangements of immunological proteins, such as cytokines and acute phase reactants, and their impact on outcomes in HIV-associated DLBCL (HIV-DLBCL) is lacking. This study assessed the levels and prognostic relevance of interleukin (IL)-6, IL-10 and Transforming Growth Factor Beta (TGFβ), the acute phase proteins C-reactive protein (CRP) and ferritin; serum free light chains (SFLC) (elevation of which reflects a prolonged pro-inflammatory state); and the activity of the immunosuppressive enzyme Indoleamine 2,3-dioxygenase (IDO)in South African patients with DLBCL...
2024: Frontiers in Cellular and Infection Microbiology
https://read.qxmd.com/read/38633575/marginal-zone-lymphoma-international-prognostic-index-a-unifying-prognostic-index-for-marginal-zone-lymphomas-requiring-systemic-treatment
#19
JOURNAL ARTICLE
Luca Arcaini, Côme Bommier, Juan Pablo Alderuccio, Michele Merli, Nicole Fabbri, Maria Elena Nizzoli, Matthew J Maurer, Vittoria Tarantino, Simone Ferrero, Sara Rattotti, Annalisa Talami, Roberta Murru, Arushi Khurana, Raphael Mwangi, Marina Deodato, Emanuele Cencini, Francesca Re, Carlo Visco, Andrew L Feldman, Brian K Link, Marcia Torresan Delamain, Michele Spina, Ombretta Annibali, Alessandro Pulsoni, Andrés J M Ferreri, Caterina Cecilia Stelitano, Elsa Pennese, Thomas M Habermann, Luigi Marcheselli, Sunwoo Han, Isildinha M Reis, Marco Paulli, Izidore S Lossos, James R Cerhan, Stefano Luminari
BACKGROUND: Marginal zone lymphomas (MZL), comprised of three unique but related subtypes, lack a unifying prognostic score applicable to all the patients in need for systemic chemotherapy and/or immunotherapy. METHODS: Patients from the prospective NF10 study (NCT02904577) with newly diagnosed MZL and receiving frontline systemic therapy at diagnosis or after observation were used to train a prognostic model. The primary endpoint was progression-free survival (PFS) from start of treatment...
June 2024: EClinicalMedicine
https://read.qxmd.com/read/38632203/adverse-events-of-nivolumab-plus-ipilimumab-versus-nivolumab-plus-cabozantinib-a-real-world-pharmacovigilance-study
#20
JOURNAL ARTICLE
Yurie Oka, Jun Matsumoto, Tatsuaki Takeda, Naohiro Iwata, Takahiro Niimura, Aya Fukuma Ozaki, Kensuke Bekku, Hirofumi Hamano, Motoo Araki, Keisuke Ishizawa, Yoshito Zamami, Noritaka Ariyoshi
BACKGROUND: No head-to-head clinical trials have compared the differences in adverse events (AEs) between nivolumab plus ipilimumab (NIVO-IPI) and nivolumab plus cabozantinib (NIVO-CABO) in the treatment of metastatic renal cell carcinoma (mRCC). AIM: We analysed the two largest real-world databases, the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the World Health Organization's VigiBase, to elucidate the differences in AEs between NIVO-IPI and NIVO-CABO...
April 17, 2024: International Journal of Clinical Pharmacy
keyword
keyword
8788
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.